Lopinavir/ritonavir, Arbidol Can't Treat COVID-19 Adults

Lopinavir/ritonavir and Arbidol are not effective for mild-to-moderate COVID-19 in adults, according to an exploratory randomized, controlled study, which assessed treatments for COVID-19.

No drug improves the clinical outcome of patients hospitalized with mild-to-moderate COVID-19 over supportive care, according to the study in Med, a new medical journal published by Cell Press.

"We found that neither //lopinavir/ritonavir nor Arbidol could benefit clinical outcomes for patients and that they might bring some side effects," says co-senior author Linghua Li, Vice Director of the Centre for Infectious Diseases of Guangzhou Eighth People's Hospital in Guangzhou, China.

‘Researchers should keep working to find an effective antiviral regimen against COVID-19. The general public shouldn't fear because of no existing antiviral medicine.’
Read More..

"And although the sample size is small, we believe it could still provide meaningful suggestions for proper application of LPV/r or Arbidol for COVID-19."

The researchers chose to study LPV/r and Arbidol because the antivirals had been selected as candidates for treating COVID-19 in a guidance issued on February 19, 2020, by the National Health Commission of China, based on in vitro cell tests and previous clinical data from SARS and MERS.

Other researchers had already found that LPV/r did not improve outcomes for patients with severe COVID-19.

Coronavirus
Coronaviruses infect animals, humans, and birds. Human coronaviruses, such as SARS, MERS, and 2019-nCoV cause respiratory distress and even death. The S protein is the infectious agent of the virus.

"It is important to know if lopinavir/ritonavir is effective for mild/moderate cases with COVID-19," Li says. "If it is, the medicine could prevent mild/moderate cases from deteriorating to severe status and help reduce the mortality rate."

The study assessed 86 patients with mild-to-moderate COVID-19, with 34 randomly assigned to receive LPV/r, 35 to Arbidol, and 17 with no antiviral medication as a control. All three groups showed similar outcomes at 7 and 14 days, with no differences between groups in the rates of fever reduction, cough alleviation, or improvement of chest CT scan.

Patients in both drug groups experienced adverse events such as diarrhea, nausea, and loss of appetite during the follow-up period, while no apparent adverse event occurred in the control group.

"Our findings suggest that we need to cautiously consider before using these drugs," Li says.

"Researchers need to keep working to find a really effective antiviral regimen against COVID-19, but meanwhile, any conclusions about antiviral regimens need strict and scientific clinical trials and appropriate caution.

The general public, however, shouldn't panic just because currently there's no specific antiviral medicine currently. Quarantine and good personal health protection could help us prevent people from getting infected with COVID-19, and even in case of infection, the present comprehensive treatment can still enable the vast majority of patients to return to health."

Source-Eurekalert